AH
TNGX icon

Aviva Holdings’s Tango Therapeutics TNGX Stock Holding History

Aviva Holdings’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-26,961
Closed -$304K – 3
2023
Q3 		$304K Hold
26,961
– – 0.2% 4
2023
Q2 		$90K Hold
26,961
– – 0.07% 4
2023
Q1 		$106K Hold
26,961
– – 0.07% 4
2022
Q4 		$195K Hold
26,961
– – 0.11% 4
2022
Q3 		$98K Hold
26,961
– – 0.04% 5
2022
Q2 		$122K Hold
26,961
– – 0.04% 5
2022
Q1 		$204K Hold
26,961
– – 0.05% 5
2021
Q4 		$295K Hold
26,961
– – 0.05% 5
2021
Q3 		$349K Buy
+26,961
New +$323K 0.05% 5

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Aviva Holdings's TNGX Position: Q4 2023 in Review

Aviva Holdings sold out of Tango Therapeutics (TNGX) in Q4 2023, closing a stake of 26,961 shares — an estimated $304K sold.

Aviva Holdings first reported a position in TNGX in Q3 2021 and held it in 9 quarters. The position peaked at $349K in Q3 2021. 121 funds tracked by Wall St. Rank hold TNGX as of Q4 2023.

  • Aviva Holdings reported no remaining Tango Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Aviva Holdings sold 26,961 Tango Therapeutics shares in Q4 2023, an estimated $304K.
  • Aviva Holdings first reported a position in Tango Therapeutics in Q3 2021 and held it in 9 quarters.
  • Aviva Holdings's Tango Therapeutics position peaked at $349K in Q3 2021.
  • 121 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2023.

Based on Aviva Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.